Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Targeted and Non-targeted Microbubbles for Pediatric Applications

Award Number: R41HD089823
ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2016
PERIOD OF PERFORMANCE END DATE: 02/28/2018

Group Awards By:

View Award Description

Targeted and Non-targeted Microbubbles for Pediatric Applications - Project Summary Staphylococcus is the most common cause of community- and hospital-acquired infective endocarditis worldwide. Staphylococcal (S. aureus) endocarditis is a serious health problem in children and adults that carries high morbidity and mortality. The incidence of this disease is increasing due to healthcare advances with widespread use of intra-cardiac devices and prosthetic heart valves, and greater prevalence of valvular heart disease. One of the key limitations with antibiotic therapy for S. aureus endocarditis is poor drug penetration into the vegetation. The shear jets induced by ultrasound-mediated cavitation (UMC) of circulating microbubbles (MBs) have been utilized to dissolve thrombi within vessels and the microvasculature. Fibrin affords an attractive target for developing targeted MBs in the treatment of endocarditis with ultrasound, as the conjugate binding permits MB adherence even in conditions of high shear stress. We propose to develop fibrin- targeted MBs, and evaluate the effectiveness of fibrin-targeted MBs and UMC co-administered with systemic vancomycin in the treatment of S. aureus aortic valve endocarditis. After production of bioconjugate and fibrin- targeted MBs, we will evaluate MB binding to the fibrin target under conditions of variable shear stress. We hypothesize that UMC of fibrin targeted MB will improve vancomycin activity against S. aureus by improving antibiotic penetration into the vegetation, and promoting vegetation clearance. Furthermore, we hope to demonstrate that the reductions in vegetation size by UMC may decrease complications including valvular regurgitation, perivalvular extension and embolization, resulting in improved outcomes including survival. We will examine this therapeutic approach in an established rabbit model of S. aureus endocarditis, randomized to receive either transthoracic UMC application with systemic vancomycin co-administered with fibrin-targeted MBs, versus vancomycin alone. Bacterial counts (colony forming units/ml) in the treated vegetation will be quantified as the primary outcome variable. Residual bacterial counts in peripheral organs and brain as a result of embolic phenomena will also be quantified. Secondary outcomes of serial vegetation size, valvular regurgitation and five-day survival will be tested. Successful completion of this research could significantly impact the clinical management of this life-threatening disease. Results of these studies will be used to advance this non-invasive therapeutic strategy into an Investigational New Drug application.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2018 ( Subtotal = $0 )
2018	2016	NUVOX PHARMA, L.L.C.	1635 E. 18TH ST	TUCSON	AZ	85719	PIMA	USA	Child Health and Human Development Extramural Research	000	1	4/5/2018	NEW	$0
														Subtotal = $0

Issue Date FY: 2016 ( Subtotal = $243,164 )
2016	2016	NUVOX PHARMA LLC	1635 EAST 18TH STREET	TUCSON	AZ	85715	PIMA	USA	Child Health and Human Development Extramural Research	000	1	8/25/2016	NEW	$243,164
														Subtotal = $243,164

Grand Total All Awards = $243,164

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeted and Non-targeted Microbubbles for Pediatric Applications

Award Number: R41HD089823

ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2016

PERIOD OF PERFORMANCE END DATE: 02/28/2018

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer